Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Employees

1,017

Sector

Biotechnology & Medical Research

Calendar

09-08 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
18/07/25	169.90 $	-4.12%	617,646
17/07/25	177.20 $	+1.03%	353,205
16/07/25	175.40 $	+0.37%	426,384
15/07/25	174.75 $	-0.08%	314,308
14/07/25	174.88 $	-0.04%	320,526

Delayed Quote Nasdaq, July 18, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

145.77EUR

Average target price

201.39EUR

Spread / Average Target

+38.15%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 18/07/2025 BST			5-day change	1st Jan Change
169.90 ^USD	-4.12%		-2.89%	+23.41%

07-14	Ascendis Pharma's Phase 3 Trial of TransCon PTH to Treat Endocrine Disease Shows Sustained Efficacy	MT
07-14	Ascendis Pharma A/S Announces New Data from Week 156 of its Phase 3 PaTHway Trial Confirms Sustained Response to TransCon PTH Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life	CI

Capitalization	8.83B 10.29B 8.22B 7.65B 14.12B 886B 15.76B 99.36B 37.51B 415B 38.59B 37.79B 1,527B	P/E ratio 2025 *	-41.3x	P/E ratio 2026 *	101x
Enterprise value	9.41B 10.97B 8.77B 8.16B 15.05B 945B 16.81B 106B 39.99B 443B 41.14B 40.29B 1,628B	EV / Sales 2025 *	14.5x	EV / Sales 2026 *	8.17x
Free-Float	97.58%	Yield 2025 *	-	Yield 2026 *	-

Ascendis Pharma's Phase 3 Trial of TransCon PTH to Treat Endocrine Disease Shows Sustained Efficacy	07-14	MT
Ascendis Pharma A/S Announces New Data from Week 156 of its Phase 3 PaTHway Trial Confirms Sustained Response to TransCon PTH Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life	07-14	CI
European Equities Traded in the US as ADRs Edge Up in Monday Trading	07-14	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	07-09	MT
Ascendis Pharma A/S to Share Its Latest Endocrinology Rare Disease Data At Endo 2025	07-07	CI
European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading	07-01	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	06-25	MT
Oppenheimer Raises Price Target on Ascendis Pharma to $224 From $215, Maintains Outperform Rating	06-13	MT
Allarity Therapeutics, Inc Announces Changes to Board of Directors	06-11	CI
Ascendis Pharma Set to Exceed Q2 Expectations, RBC Says	06-10	MT
Ascendis Pharma A/S - Special Call	06-09
Ascendis Pharma A/S Announces Week 26 Interim Analysis Results from Its Ongoing Coach Trial	06-09	CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-02	MT

Oppenheimer Raises Price Target on Ascendis Pharma to $224 From $215, Maintains Outperform Rating	06-13	MT
Morgan Stanley Upgrades Ascendis Pharma to Overweight From Equalweight, Boosts Price Target to $250 From $180	05-05	MT
RBC Raises Price Target on Ascendis Pharma to $210 From $205, Keeps Outperform, Speculative Risk	05-02	MT
RBC Initiates Ascendis Pharma at Outperform, Speculative Risk With $205 Price Target	04-16	MT
Oppenheimer Adjusts Ascendis Pharma A/S Price Target to $180 From $190, Maintains Outperform Rating	11-15	MT

Ascendis Pharma A/S Share Price

Equities

ASND

US04351P1012

Biotechnology & Medical Research

Valuation: Ascendis Pharma A/S

Chart: Ascendis Pharma A/S

Latest news: Ascendis Pharma A/S

Last Transcript: Ascendis Pharma A/S

Analysts' recommendations: Ascendis Pharma A/S

Press Releases: Ascendis Pharma A/S

News in other languages: Ascendis Pharma A/S

Quotes and Performance

Course Extremes

Managers and Directors: Ascendis Pharma A/S

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

New 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Quality of Life	07-14	AQ
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025	07-08	AQ
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ENDO 2025	07-07	AQ
Ascendis Pharma A/S : COACH Trial Interim Topline Week 26 Data	06-09	PU
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial	06-09	AQ

Insubmersibles	02-13
En direct des marchés : EssilorLuxottica brille encore, Alibaba flambe, Chevron taille dans ses effectifs	02-13
Trump essaie la carotte après le bâton	01-14
En direct des marchés : le TikTok de Musk, Lindt et Cucinelli publient, Amundi temporise en Italie	01-14
EQS-Adhoc : HBM Healthcare Investments erzielt im Geschäftsjahr 2020/2021 einen Jahresgewinn von CHF 756 Millionen; Erhöhung der beantragten Barausschüttung auf total CHF 12.50 je Aktie.	07/05/21

1 day	-4.12%
1 week	-2.89%
Current month	-1.56%
1 month	-0.47%
3 months	+2.94%
6 months	+32.60%
Current year	+23.41%

1 week	169.52	179.96
1 month	166.84	180.78
Current year	118.03	183
1 year	111.09	183
3 years	64.33	183
5 years	61.58	183.98
10 years	11.92	183.98

Manager	Title	Age	Since
Jan Mikkelsen CEO	Chief Executive Officer	66	30/11/2007
Scott Smith DFI	Director of Finance/CFO	52	07/08/2016
Stina Singel CTO	Chief Tech/Sci/R&D Officer	52	30/04/2020

Director	Title	Age	Since
Jan Mikkelsen BRD	Director/Board Member	66	30/11/2007
Albert Cha CHM	Chairman	53	27/05/2021
Lisa Bright BRD	Director/Board Member	58	31/03/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ASCENDIS PHARMA A/S	-4.12%	-2.89%	+24.45%	+98.71%	10.73B
LONZA GROUP AG	-0.04%	+1.03%	+10.09%	+1.28%	50.03B
BEONE MEDICINES LTD.	+1.45%	+17.68%	+93.74%	+70.52%	34.39B
CELLTRION, INC.	-0.06%	+0.95%	+4.78%	+11.89%	28.64B
IQVIA HOLDINGS INC.	-1.60%	-1.33%	-28.56%	-24.54%	28.24B
EUROFINS SCIENTIFIC SE	+1.19%	+1.25%	+26.23%	-21.75%	12.59B
ICON PUBLIC LIMITED COMPANY	-2.27%	-4.64%	-56.21%	-29.79%	11.67B
TEMPUS AI, INC.	+0.54%	+7.21%	+51.92%	-	10.5B
QIAGEN N.V.	+0.25%	+0.48%	+12.53%	-1.16%	10.45B
MEDPACE HOLDINGS, INC.	-2.28%	-3.60%	-26.44%	+114.20%	9.17B
Average	-0.75%	+1.07%	+11.25%	+24.37%	20.64B
Weighted average by Cap.	-0.36%	+2.67%	+16.61%	+18.43%

	2025 *	2026 *
Net sales	647M 755M 603M 561M 1.04B 64.98B 1.16B 7.29B 2.75B 30.47B 2.83B 2.77B 112B	1.14B 1.33B 1.07B 992M 1.83B 115B 2.04B 12.88B 4.86B 53.85B 5B 4.9B 198B
Net income	-223M -260M -208M -194M -357M -22.43B -399M -2.51B -949M -10.51B -977M -957M -38.65B	162M 189M 151M 141M 259M 16.27B 289M 1.82B 689M 7.63B 709M 694M 28.04B
Net Debt	584M 681M 544M 506M 934M 58.61B 1.04B 6.57B 2.48B 27.48B 2.55B 2.5B 101B	521M 607M 485M 451M 833M 52.27B 930M 5.86B 2.21B 24.51B 2.28B 2.23B 90.09B